A note from history: Landmarks in history of cancer, part 7

Cancer

Volumn 121, Issue 15, 2015, Pages 2480-2513

  Hajdu, Steven I ^a   Vadmal, Manjunath ^b   Tang, Ping ^c  

^a Pathology Consultants   (United States)

^b LAC USC MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

cancer epidemiology; cancer prevention; cancerogenesis oncogenes; clinical laboratory tests detecting cancers precancerous lesions; diagnostic radiology radiation therapy; etiology causation of cancer; history of cancer; immunotherapy; medical oncology; surgical pathology oncology

Indexed keywords

CELL TRANSFORMATION; EDUCATION; GENETICS; HISTORY; HUMAN; INFORMATION DISSEMINATION; NEOPLASMS; ONCOLOGY; PHYSIOLOGY; PROFESSIONAL PRACTICE; PUBLICATION; STANDARDS; STATISTICS AND NUMERICAL DATA; TUMOR VIRUS;

CELL TRANSFORMATION, NEOPLASTIC; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFORMATION DISSEMINATION; MEDICAL ONCOLOGY; NEOPLASMS; ONCOGENIC VIRUSES; PROFESSIONAL PRACTICE; PUBLICATIONS;

EID: 84937519530     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29365     Document Type: Review

References (438)

1. Hajdu SI,. A note from history: landmarks in history of cancer, part 1. Cancer. 2011; 117: 1097-1102.
2. Hajdu SI,. A note from history: landmarks in history of cancer, part 2. Cancer. 2011; 117: 2810-2820.
3. Hajdu SI,. A note from history: landmarks in history of cancer, part 3. Cancer. 2012; 118; 1155-1168.
4. Hajdu SI,. A note from history: landmarks in history of cancer, part 4. Cancer. 2012; 118: 4914-4928.
5. Hajdu SI, Darvishian F,. A note from history: landmarks in history of cancer, part 5. Cancer. 2013; 119: 1450-1466.
6. Hajdu SI, Vadmal M,. A note from history: landmarks in history of cancer, part 6. Cancer. 2013; 119: 4058-4082.
7. Strauss MJ,. Lung Cancer: Clinical Diagnosis and Treatment. New York: Grune & Stratton; 1977.
8. Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. Philadelphia, PA: Lippincott Williams & Wilkins; 1996.
9. Rosen PP,. Breast Pathology. Philadelphia, PA: Lippincott-Raven; 1996.
10. Hajdu SI,. Pathology of Soft Tissue Tumors. Philadelphia, PA: Lea & Febiger; 1979.
11. Dahlin DC,. Bone Tumors. Springfield, IL: Charles C. Thomas; 1978.
12. Copland EM, ed. Surgical Oncology. New York: John Wiley & Sons; 1983.
13. Perez CA, Brady LW, eds. Principles and Practice of Radiation Oncology. Philadelphia, PA: Lippincott-Raven; 1987.
14. Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 1994.
15. Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. Genitourinary Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 1996.
16. Percy C, Van Holten V, Muir C, eds. International Classification of Diseases for Oncology. Geneva, Switzerland: World Health Organization; 1971.
17. American Joint Committee for Cancer. Manual for Staging of Cancer. Chicago, IL: American Joint Committee for Cancer Staging and End-Results Reporting; 1977.
18. Schottenfeld D, Fraumeni JF Jr, eds. Cancer Epidemiology and Prevention. Philadelphia, PA: WB Saunders; 1982.
19. Cossman J, ed. Molecular Genetics in Cancer Diagnosis. New York: Elsevier; 1990.
20. Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia, PA: Saunders-Elsevier; 1995.
21. Holland JF, Frei E, eds. Cancer Medicine. Philadelphia, PA: Lea & Febiger; 1973.
22. DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Philadelphia, PA: JB Lippincott; 1982.
23. DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997.
24. Hajdu SI,. Thoughts about the cause of cancer. Cancer. 2006; 106: 1643-1649.
25. Lawley PD,. Historical origins of current concepts of carcinogenesis. Adv Cancer Res. 1994; 65: 17-111.
26. Cooper GM,. Elements of Human Cancer. Boston, MA: Jones and Bartlett; 1992.
27. Hoover R, Fraumeni JF Jr,. Risk of cancer in renal-transplant recipients. Lancet. 1973; 2: 55-57.
28. Penn I,. Cancers complicating organ transplantation. N Engl J Med. 1990; 323: 1767-1769.
29. Beasly RP, Wang LY, Lin CC, Chien CS,. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981; 2: 1129-1133.
30. Wong VC, Ip HM, Reesink HW, et al., Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomized placebo-controlled study. Lancet. 1984; 1: 921-926.
31. Oriel JD, Whimster IW,. Carcinoma in situ associated with virus-containing anal warts. Br J Dermatol. 1971; 84: 71-73.
32. zur Hausen H,. Condylomata acuminata and human genital cancer. Cancer Res. 1976; 36: 794-794.
33. zur Hausen H,. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol. 1977; 78: 1-30.
34. Durst M, Gissman L, Ikenberg H, zur Hausen H,. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A. 1983; 80: 3812-3815.
35. Munger K, Phelps WC, Bubb V, Howle PM, Schlegel R,. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol. 1989; 63: 4417-4421.
36. Remmink AJ, Walboomers JM, Helmerhorst TJ, et al., The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer. 1995; 61: 306-311.
37. Syrjanen K, Syrjanen S, Lamberg M, Pyrhonen S, Nuutinen J,. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg. 1983; 12: 418-424.
38. Brandsma JL, Abramson AL,. Association of papillomavirus with cancers of the head and neck. Arch Otolaryngol Head Neck Surg. 1989; 115: 621-625.
39. Stremlau A, Gissmann L, Ikenberg H, Stark M, Bannasch P, zur Hausen H,. Human papillomavirus type 16 related DNA in an anaplastic carcinoma of the lung. Cancer. 1985; 55: 1737-1740.
40. Beju-Thivolet F, Liagre N, Chignol MC, Chardonnet Y, Patricot LM,. Detection of human papillomavirus DNA in squamous bronchial metaplasia and squamous cell carcinomas of the lung by in situ hybridization using biotinylated probes in paraffin-embedded specimens. Hum Pathol. 1990; 21: 111-116.
41. Urmacher C, Myskowski P, Ochoa M Jr, Kris M, Safai B,. Outbreak of Kaposi's sarcoma with cytomegalovirus infection in young homosexual men. Am J Med. 1982; 72: 569-575.
42. Lobenthal AW, Hajdu SI, Urmacher C,. Cytologic findings in homosexual males with acquired immunodeficiency. Acta Cytol. 1983; 27: 597-604.
43. Dahling JR, Weiss NS, Klopfenstein LL, Cochran LE, Chow WH, Daifuku R,. Correlation of homosexual behavior and the incidence of anal cancer. JAMA. 1982; 247: 1988-1990.
44. Rosenblum ML, Levy RM, Bredesen DE, So YT, Wara W, Ziegler JL,. Primary central nervous system lymphoma in patients with AIDS. Ann Neurol. 1988; 23 (suppl): S13-S16.
45. Marshall BJ, Warren JR,. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1: 1311-1315.
46. Personnet J, Friedman GD, Vandersteen DP, et al., Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325: 1127-1131.
47. Herbst AL, Ulfelder H, Poskanzer DC,. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971; 284: 878-881.
48. Bradford JB,. Angiosarcoma of the liver following vinyl chloride exposure. JAMA. 1974; 229: 53-54.
49. Naef AP, Savary M, Ozzello L,. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg. 1975; 70: 826-835.
50. Belladonna JA, Hajdu SI, Bains MS, Winawer SJ,. Adenocarcinoma in situ of Barrett's esophagus diagnosed by endoscopic cytology. N Engl J Med. 1974; 291: 895-896.
51. Haggitt RC, Tryzelaar J, Ellis FH, Colcher H,. Adenocarcinoma complicating columnar-lined (Barrett's) esophagus. Am J Clin Pathol. 1978; 70: 1-5.
52. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr,. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991; 265: 1287-1289.
53. Smith DC, Prentice R, Thompson DJ, Hermann WL,. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975; 293: 1164-1167.
54. Ross RK, Paganini-Hill A, Gerkins VR, et al., A case-control study of menopausal estrogen therapy and breast cancer. JAMA. 1980; 243: 1635-1639.
55. Steinberg KK, Thacker SB, Smith SJ, et al., A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991; 265: 1985-1990.
56. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997; 350: 1047-1059.
57. Greenwald P, Kovasznay B, Collins DN, Therriault G,. Sarcomas of soft tissues after Vietnam service. J Natl Inst Health. 1984; 73: 1107-1109.
58. Lowrance WW, ed. Public Health Risks of the Dioxins. New York: The Rockefeller University Press; 1983.
59. Karon JM, De Stefano F, Devine OJ, et al., Serum 2,3,7,8-tetrachlorodibenzo-p-dioxin levels in US Army Vietnam-era veterans. The Centers for Disease Control Veterans Health Studies. JAMA. 1988; 260: 1249-1254.
60. Knudson AG Jr, Strong LC, Anderson DE,. Heredity and cancer in man. Prog Med Genet. 1973; 9: 113-158.
61. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ,. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995; 64: 430-433.
62. Rosner F, Lee SL,. Down's syndrome and acute leukemia: myeloblastic or lymphoblastic? Report of 43 cases and review of the literature. Am J Med. 1972; 53: 203-218.
63. Stsjazhko VA, Tsyb AF, Tronko ND, Souchkevitch G, Baverstock KF,. Childhood thyroid cancer since accident at Chernobyl [letter]. BMJ. 1995; 310: 801.
64. Preston DL, Kusumi S, Tomonoga M, et al., Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res. 1994; 137 (2 suppl): S68-S97.
65. International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Man-Made Mineral Fibers and Radon. Vol 43. Lyon, France: IARC; 1988.
66. Capewell S, Wathen CG, Sankaran R, Sudlow MF,. Lung cancer in young patients. Respir Med. 1992; 86: 499-502.
67. Greco RJ, Steiner RM, Goldman S, Cotler H, Patchefsky A, Cohn HE,. Bronchoalveolar cell carcinoma of the lung. Ann Thoracic Surg. 1986; 41: 652-656.
68. Koo LC, Ho JH,. Worldwide epidemiological patterns of lung cancer in nonsmokers. Int J Epidemiol. 1990; 19 (suppl 1): S14-S23.
69. Hajdu SI,. A note from history: the first tumor pathologist. Ann Clin Laboratory Sci. 2004; 34: 355-356.
70. Varmus HE, Weiss RA, Friis RR, Levinson W, Bishop JM,. Detection of avian tumor virus-specific nucleotide sequences in avian cell DNAs (reassociation kinetics-RNA tumor viruses-gas antigen-Rous sarcoma virus, chick cells). Proc Natl Acad Sci U S A. 1972; 69: 20-24.
71. Stehelin D, Varmus HE, Bishop JM, Vogt PK,. DNA related to the transforming gene(s) of avian sarcoma virus s is present in normal avian DNA. Nature. 1976; 260: 170-173.
72. Stanbridge EJ,. Suppression of malignancy in human cells. Nature. 1976; 260: 17-20.
73. Dalla-Favera R, Martinotti S, Gallo RC, Erikson J, Croce CM,. Translocation and rearrangement of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science. 1983; 219: 963-967.
74. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science. 1987; 235: 177-182.
75. Reddy EP, Reynolds RK, Santos E, Barbacid M,. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature. 1982; 300: 149-152.
76. Bos JL, Verlaan-de Vries V, van der Eb AJ, et al., Mutation in N-ras predominate in acute myeloid leukemia. Blood. 1987; 69: 1237-1241.
77. Shih C, Shilo BZ, Goldfarb MP, Dannenberg A, Weinberg RA,. Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc Natl Acad Sci U S A. 1979; 76: 5714-5718.
78. Bishop JM,. Enemies within: the genesis of retrovirus oncogenes. Cell. 1981; 25: 5-6.
79. Yakota J, Tsunetsugu-Yakota Y, Battifora H, Le Fevre C, Cline MJ,. Alterations of myc, myb, and ras proto-oncogenes in cancers are frequent and show clinical correlation. Science. 1986; 231; 261-265.
80. Slamon DJ, Godolphin W, Jones LA, et al., Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-712.
81. Carpenter G, Cohen S,. Epidermal growth factor. Annu Rev Biochem. 1979; 48: 193-216.
82. Cuttita F, Carney DN, Mulschine J, et al., Autocrine growth factors in human small cell lung cancer. Cancer Surv. 1985; 4: 707-727.
83. Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB,. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci U S A. 1985; 82: 119-123.
84. Moses HL, Yang EY, Pietenpol JA,. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell. 1990; 63: 245-247.
85. Harris H, Miller OJ, Klein G, Worst P, Tachibana T,. Suppression of malignancy by cell fusion. Nature. 1969; 223: 363-368.
86. Knudson AG Jr,. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68: 820-823.
87. Knudson AG Jr,. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. 1985; 45: 1437-1443.
88. Fried SH, Bernards R, Rogelj S, et al., A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 1986; 323: 643-646.
89. Lane DP, Crawford LV,. T antigen is bound to a host protein in SV40-transformed cells. Nature. 1979; 278: 261-263.
90. Nigro JM, Baker SJ, Preisinger AC, et al., Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989; 342: 705-708.
91. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B,. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990; 249: 912-915.
92. Malkin D, Li FP, Strong LC, et al., Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250: 1233-1238.
93. Boland CR,. The biology of colorectal cancer. Implications for pretreatment and follow-up management. Cancer. 1993; 71 (12 suppl): 4180-4186.
94. Burmer GC, Rabinovitch PS, Haggitt RC, et al., Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology. 1992; 103: 1602-1610.
95. King CR, Kraus MH, Aaronson SA,. Amplification of a novel c-erbB-related gene in a human mammary carcinoma. Science. 1985; 229: 974-976.
96. Hall JM, Lee MK, Newman B, et al., Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990; 250: 1684-1689.
97. Easton DF, Bishop DT, Ford D, Crockford GP,. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1993; 52: 678-701.
98. Wooster R, Neuhausen SL, Mangion J, et al., Localization of a breast cancer susceptibility gene, BRCA2, to 13q12-13. Science. 1994; 265: 2088-2090.
99. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT,. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet. 1995; 9: 444-450.
100. Struewing JP, Hartge P, Wacholder S, et al., The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997; 336: 1401-1408.
101. Folkman J,., Merler E,., Abernathy C, Williams G,. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971; 133: 275-288.
102. Folkman J,. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285: 1182-1186.
103. Folkman J, Cotran R,. Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol. 1976; 16: 207-248.
104. Folkman J, Klagsbrun M,. Vascular physiology. A family of angiogenic peptides. Nature. 1987; 329: 671-672.
105. Kim KJ, Li B, Winer J, et al., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362; 841-844.
106. D'Amato RJ, Loughnan MS, Flynn E, Folkman J,. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994; 91: 4082-4085.
107. Fiedler IJ,. The biology of human cancer metastasis. Acta Oncol. 1991; 30: 669-675.
108. Hajdu SI,. The first biochemical test for detection of cancer. Ann Clin Lab Sci. 2006; 36: 222-223.
109. Manolov G, Manolova Y,. Marker band in one chromosome 14 from Burkitt lymphomas. Nature. 1972; 237: 33-34.
110. Rowley JD,. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet. 1973; 16: 109-112.
111. Kondo K, Chilcote RR, Maurer HS, Rowley JD,. Chromosome abnormalities in tumor cells from patients with sporadic Wilms' tumor. Cancer Res. 1984; 44: 5378-5381.
112. Turk-Carel C, Philip I, Berger MP, Phillip T, Lenoir GM,. Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22) (q24;q12). Cancer Genet Cytogenet. 1984; 12: 1-19.
113. de Chadarevian JP, Vekemans M, Seemayer TA,. Reciprocal translocations in small-cell sarcomas. N Engl J Med. 1984; 311: 1702-1703.
114. Takahashi T, Nau MM, Chiba I, et al., p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989; 246: 491-494.
115. Narod SA, Feunteun J, Lynch HT, et al., Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet. 1991; 338: 82-83.
116. Mitelman F,. Catalogue of chromosome aberrations in cancer. Cytogenet Cell Genet. 1983; 36 (1-2): 1-515.
117. Turk-Carel C, Philip I, Berger MP, et al., Chromosome translocation in Ewing's sarcoma. N Engl J Med. 1983; 309: 496-498.
118. Whang-Peng J, Triche TJ, Knutsen T, Miser J, Douglass EC, Israel MA,. Chromosome translocation in peripheral neuroepithelioma. N Engl J Med. 1984; 311: 584-585.
119. Aman P, Ron D, Mandahl N, et al., Rearrangement of the transcription factor gene CHOP in myxoid liposarcoma with t(12;16)(q13;p11). Genes Chromosomes Cancer. 1992; 5: 278-285.
120. Nowell PC,. The clonal evolution of tumor cell population. Science. 1976; 194: 23-28.
121. Tashjian AH, Howland BG, Melvin KEW, et al., Immunoassay of human calcitonin. N Engl J Med. 1970; 283: 890-895.
122. Aiuti F, Cerrottini JC, Coambs RRA, et al., Identification, enumeration, isolation of B and T lymphocytes from human peripheral blood. Report of a WHO-IARC-sponsored workshop on human B and T cells, London, 15-17 July 1974. Scand J Immunol. 1974; 3: 521-523.
123. Waldman TA, McIntire KR,. The use of radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy. Cancer. 1974; 34 (4 suppl): 1510-1515.
124. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS,. Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46: 219-234.
125. Vaitukaitis JL, Braunstein GD, Ross GT,. A radioimmunoassay which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone. Am J Obstet Gynecol. 1972; 113: 751-758.
126. Wanebo HJ, Rao B, Pinsky CM, et al., Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med. 1978; 299: 448-451.
127. Mughal AW, Hortobagyi GN, Fritsche HA, Buzdar AU, Yap HY, Blumenschein GR,. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA. 1983; 249: 1881-1886.
128. Wang MC, Papasidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM,. Prostate antigen: a new potential marker for prostatic cancer. Prostate. 1981; 2: 89-96.
129. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E,. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317: 909-916.
130. Del Villano BC, Brennan S, Brock P, et al., Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983; 29: 549-552.
131. Bast RC Jr, Klug TL, St John E, et al., A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983; 309: 883-887.
132. Barlogie B, Raber MN, Schumann J, et al., Flow cytometry in clinical cancer research. Cancer Res. 1983; 43: 3982-3997.
133. Urba WJ, Longo DL,. Cytologic, immunologic, and clinical diversity in non-Hodgkin's lymphoma: therapeutic implication. Semin Oncol. 1985; 12: 250-267.
134. Sias PE, Kotts CE, Vetterlein D, Shepard M, Wong WL,. ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. J Immunol Methods. 1990; 132: 73-80.
135. Snijders PJ, van den Brule AJ, Schrinjnemakers HF, Snow G, Meijer CJ, Walboomers JM,. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol. 1990; 71: 173-181.
136. Rozendaal L, Walboomers JM, van der Linden JC, et al., PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smear. Int J Cancer. 1996; 68: 766-769.
137. Barillari P, Bolognese A, Chirletti P, Cardi M, Sammartino P, Stipa V,. Role of CEA, TPA, and CA 19-9 in the early detection of localized and diffuse recurrent rectal carcinoma. Dis Colon Rectum. 1992; 35: 471-476.
138. Jacobs IJ, Skates S, Davies AP, et al., Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ. 1996; 313: 1355-1358.
139. Christopherson WM, Lundin FE Jr, Mendez WM, Parker JE,. Cervical cancer control: a study of morbidity and mortality trends over a twenty-one-year period. Cancer. 1976; 38: 1357-1366.
140. Winawer SJ, Sherlock P, Hajdu SI,. The role of upper gastrointestinal endoscopy in patients with cancer. Cancer. 1976; 37 (1 suppl): 440-448.
141. Gilbertsen VA, Nelms JM,. The prevention of invasive cancer of the rectum. Cancer. 1978; 41: 1137-1139.
142. Winaver SJ, Leidner SD, Hajdu SI, Sherlock P,. Colonoscopic biopsy and cytology in the diagnosis of colon cancer. Cancer. 1978; 42: 2849-2853.
143. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS,. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992; 326: 653-657.
144. Mandel JS, Bond JH, Church TR, et al., Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993; 328: 1365-1371.
145. Miki Y, Swensen J, Schattuck-Eidens D, et al., A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266: 66-71.
146. Muller AD, Sonnenberg A,. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med. 1995; 123: 904-910.
147. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT,. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst. 1994; 86: 494-499.
148. Tabar L, Fagerberg CJ, Gad A, et al., Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985; 1: 829-832.
149. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE,. Risks of cancer. BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994; 343: 692-695.
150. National Institutes of Health (NIH), Office for Medical Applications of Research. NIH Consensus Development Conference Statement. Ovarian Cancer: Screening, Treatment, and Follow-Up. Bethesda, MD: National Institutes of Health; 1994.
151. Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, Martini N,. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest. 1984; 86; 44-53.
152. Kaneko M, Eguchi K, Ohmatsu H, et al., Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology. 1996; 201; 798-802.
153. Eddy D., ACS report on the cancer-related health checkup. CA Cancer J Clin. 1980; 30: 193-240.
154. National Cancer Institute. Working Guidelines for Early Cancer Detection. Bethesda, MD: National Cancer Institute, Early Detection Branch, Division of Cancer Prevention and Control; 1987.
155. Woods JA, Davis JM, Kohut ML, Ghaffar A, Mayer EP, Pate RR,. Effects of exercise on the immune response to cancer. Med Sci Sports Exerc. 1994; 26: 1109-1115.
156. Kasugai T, Kuno N, Kizu M, Kobayashi S, Hattori K,. Endoscopic pancreatocholangiography: II. The pathological endoscopic pancreatocholangiogram. Gastroenterology. 1972; 63: 227-234.
157. Quingley MM,. Overview of gestational trophoblastic neoplasia. N Y State J Med. 1973; 73: 1869-1874.
158. Sargent EN, Turner AF, Gordonson J, Schwinn CP, Pashky O,. Percutaneous pulmonary needle biopsy. Report of 350 patients. Am J Roentgenol Rad Ther Nucl Med. 1974; 122: 758-768.
159. Ter-Pogossian MM, Phelps ME, Hoffman EJ, Mullani NA,. A positron emission transaxial tomography for nuclear medicine imaging (PETT). Radiology. 1975; 114: 89-98.
160. 131I-labeled antibodies by radionuclide imaging. Radiology 1975; 116: 445-448.
161. Haaga JR, Alfidi RJ,. Precise biopsy localization by computed tomography. Radiology. 1976; 118: 603-607.
162. Harada H, Sasaki T, Yamamoto N, Tanaka J, Tomiyama Y,. Assessment of endoscopic aspiration cytology and endoscopic retrograde cholangio-pancreatography in patients with cancer of the hepato-biliary tract. Part II. Gastroenterol Jpn. 1977; 12: 59-64.
163. Bolmgren J, Jacobson B, Nordenstrom B,. Stereotaxic instrument for needle biopsy of the mamma. AJR Am J Roentgenol. 1977; 129: 121-125.
164. Sinner WN,. Pulmonary neoplasms diagnosed with transthoracic needle biopsy. Cancer. 1979; 43: 1533-1540.
165. Ohto M, Karasawa E, Tsuchiya Y, et al., Ultrasonically guided percutaneous contrast medicine injection and aspiration biopsy using a real-time puncture transducer. Radiology. 1980; 136: 171-176.
166. Husband JE, Golding SJ,. The role of computed tomography-guided needle biopsy in an oncology service. Clin Radiol. 1983; 34: 255-260.
167. Brant-Zawadzki M, Norman D, Newton TH, et al., Magnetic resonance of the brain: the optimal screening technique. Radiology. 1984; 152: 71-77.
168. Zimmer WD, Berquist TH, McLeod RA, et al., Bone tumors: magnetic resonance imaging versus computed tomography. Radiology. 1985; 155: 709-718.
169. Carrasquillo JA, Krohn KA, Beaumer P, et al., Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep. 1984; 68: 317-328.
170. Hricak H,. Urologic cancer. Methods of early detection and future developments. Cancer. 1987; 60 (3 suppl): 677-685.
171. 18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol. 1987; 22: 360-371.
172. Bourne TH, Campbell S, Steer CV, Royston P, Whitehead MI, Collins WP,. Detection of endometrial cancer by transvaginal ultrasonography with color flow imaging and blood flow analysis: a preliminary report. Gynecol Oncol. 1991; 40: 253-259.
173. Hurter T, Hanrath P,. Endobronchial sonography: feasibility and preliminary results. Thorax. 1992; 47: 565-567.
174. Moriyama N, Iwata R, Wakao F, Ootani M, Oomatsu H,. Helical computed tomography scanning of the thorax and abdomen. Jpn J Clin Oncol. 1993; 23: 156-161.
175. Uren RF, Howman-Giles RB, Shaw HM, Thompson JF, McCarthy WH,. Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med. 1993; 34: 1435-1440.
176. Bury T, Dowlati A, Paulus P, et al., Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J. 1996; 9: 410-414.
177. Klein JS, Salomon G, Stewart EA,. Transthoracic needle biopsy with a coaxially placed 20-gauge automated cutting needle: results in 122 patients. Radiology. 1996; 198: 715-720.
178. Baker LH,. Breast Cancer Detection Demonstration Project: five-year summary report. CA Cancer J Clin. 1982; 32: 196-225.
179. Homer MJ, Pile-Spellman ER,. Needle localization of occult breast lesions with a curved-end retractable wire: technique and pitfalls. Radiology. 1986; 161: 547-548.
180. Bruneton JN, Carmella E, Hery M, Aubanel D, Manzino JJ, Picard JL,. Axillary lymph node metastases in breast cancer: preoperative direction with US. Radiology. 1986; 158: 325-326.
181. Krag DN, Weaver DL, Alex JC, Fairbank JT,. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993; 2: 335-339; discussion 340.
182. Hajdu SI,. A note from history: the first printed case reports of cancer. Cancer. 2010; 116; 2493-2498.
183. Conley J, Lattes R, Orr W,. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer. 1971; 28: 914-936.
184. Mihm MC Jr, Clark WH Jr, From L,. The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanoma. N Engl J Med. 1971; 284: 1078-1082.
185. Lavin P, Hajdu SI, Foote FW Jr,. Gastric and extragastric leiomyoblastomas: clinicopathologic study of 44 cases. Cancer. 1972; 29: 305-311.
186. Toker C,. Trabecular carcinoma of the skin. Arch Dermatol. 1972; 105: 107-110.
187. Kerr JF, Wyllie AH, Currie AR,. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972; 26: 239-257.
188. Woodruff JM, Chernik NL, Smith MC, Millett WB, Foote FW Jr,. Peripheral nerve tumors with rhabdomyosarcomatous differentiation (malignant "Triton" tumors). Cancer. 1973; 32: 426-439.
189. Clement BP, Scully R,. Mullerian adenosarcoma of the uterus. A clinicopathologic analysis of ten cases of a distinctive type of Mullerian mixed tumor. Cancer. 1974; 34: 1138-1149.
190. Tang CK, Hajdu SI,. Neuroblastoma in adolescence and adulthood. N Y State J Med. 1975; 75: 1434-1438.
191. Seemayer TA, Thelmo WL, Bolande RP, Wiglesworth WF,. Peripheral neuroectodermal tumors. Prospect Pediatr Pathol. 1975; 2: 151-172.
192. Hajdu SI, Shiu MH, Fortner JG,. Tendosynovial sarcoma: a clinicopathologic study of 136 cases. Cancer. 1977; 39: 1201-1217.
193. Dahlin DC, Unni KK,. Osteosarcoma of bone and its important recognizable varieties. Am J Surg Pathol. 1977; 1: 61-72.
194. Cubilla AL, Woodruff JM,. Primary carcinoid tumor of the breast: a report of 8 patients. Am J Surg Pathol. 1977; 1: 283-292.
195. Hart WR,. Ovarian epithelial tumors of borderline malignancy (carcinoma of low malignant potential). Hum Pathol. 1977; 8: 541-549.
196. Uehiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H,. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977; 50: 481-492.
197. Kim H, Dorfman RF, Rappaport H,. Signet ring cell lymphoma. A rare morphologic and functional expression of nodular (follicular) lymphoma. Am J Surg Pathol. 1978; 2: 119-132.
198. Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW,. Infiltrating lobular carcinoma of the breast. Histopathology. 1982; 6: 149-161.
199. Mazur MT, Clark HB,. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol. 1983; 7: 507-519.
200. Isaacson P, Wright DH,. Malignant lymphoma of mucosal-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983; 52: 1410-1416.
201. McNeal JE, Bostwick DG,. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol. 1986; 17: 64-71.
202. Nador RG, Cesarman E, Chadburn A, et al., Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996; 88: 645-656.
203. Gleason DF,. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966; 50: 125-128.
204. Gleason DF, Mellinger GT,. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974; 111: 58-64.
205. Kempson RL, Bari W,. Uterine sarcomas. Classification, diagnosis, and prognosis. Hum Pathol. 1970; 1: 331-349.
206. Huvos AG, Rosen G, Marcove RC,. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977; 101: 14-18.
207. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR,. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986; 46: 2578-2581.
208. Galea MH, Blamey RW, Elston CE, Ellis IO,. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992; 22: 207-219.
209. Bennett JM, Catowsky D, Daniel MT, et al., Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33: 351-358.
210. Posner MC, Shiu MH, Newsome JL, Hajdu SI, Gaynor JJ, Brennan MF,. The desmoid tumor. Not a benign disease. Arch Surg. 1989; 124: 191-196.
211. Lowy M, Lejeune F, Heimann R, Achten G,. Fibrome desmoid-transformation en fibrosarcoma. Dermatologica. 1981; 163: 125-136.
212. Schwickerath J, Kunzig HJ,. Die spontane maligne Tramsformation einer extraabdominallen Fibromatose in ein Fibrosarkom. Geburtshilfe Frauenheilkd. 1995; 55: 173-175.
213. Greaves MF,. Analysis of the clinical and biological significance of lymphoid phenotypes in acute leukemia. Cancer Res. 1981; 41: 4752-4766.
214. National Cancer Institute sponsored study of classification on non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982; 49: 2112-2135.
215. Lagios MD, Westdahl PR, Margolin FR, Rose MR,. Ductal carcinoma in situ. Relationship of extent of noninvasive disease to frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer. 1982; 50: 1309-1314.
216. Beckwith JB,. The John Lattimer lecture. Wilms tumor and other renal tumors of childhood: an update. J Urol. 1986; 136: 320-324.
217. The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses. National Cancer Institute Workshop. JAMA. 1989; 262: 931-944.
218. Dehner LP,. Primitive neuroectodermal tumor and Ewing's sarcoma. Am J Surg Pathol. 1993; 17: 1-13.
219. Harris NL, Jaffe ES, Stein H, et al., A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84: 1361-1392.
220. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z,. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995; 180: 297-306.
221. Manual for Staging of Cancer. Chicago, IL: American Joint Committee for Cancer Staging and End-Results Reporting; 1978.
222. Enneking WF, Spanier SS, Goodman MA,. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am. 1980; 62: 1027-1030.
223. Creasman WT,. New gynecologic cancer staging. Gynecol Oncol. 1995; 58: 157-159.
224. Hsu KG, Zimmerman EA, Rudin I, LoGerfo P, Bennett S, Tannenbaum M,. Application of immunoperoxidase bridge technique in studies of tumor tissues with antibody to tumor associated antigen (TAA). In: Proceedings of the Second Conference and Workshop on Embryonic and Fetal Antigens in Cancer. Vol 2. Springfield, VA: US Department of Commerce; 1972:147-151.
225. Hsu SM, Raine L, Fanger H,. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29: 577-580.
226. Wang MC, Valenzuela LA, Murphy GP, Chu TM,. Purification of a prostate specific antigen. Invest Urol. 1979; 17: 159-163.
227. Gerdes J, Schwab U, Lemke H, Stein H,. Production of mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31: 13-20.
228. Azumi N, Battifora H, The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors. Am J Clin Pathol. 1987; 88: 286-296.
229. Drier JK, Swanson PE, Cherwitz DL, Wick MR,. S100 protein immunoreactivity in poorly differentiated carcinomas. Immunohistochemical comparison with malignant melanoma. Arch Pathol Lab Med. 1987; 111: 447-452.
230. Raemaekers F, van Niekerk C, Poels L, et al., Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas. Am J Pathol. 1990; 136: 641-655.
231. Moll R, Lowe A, Laufer J, Franke WW,. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol. 1992; 140: 427-447.
232. Jones H, Steart PV, Du Boulay CE, Roche WR,. Alpha-smooth muscle actin as a marker for soft tissue tumors: a comparison with desmin. J Pathol. 1990; 162: 29-33.
233. Shi SR, Key ME, Kalra KL,. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991; 39: 741-748.
234. Hajdu SI, Shiu MH, Brennan MF,. The role of pathologist in the management of soft tissue sarcomas. World J Surg. 1988; 12: 326-331.
235. Rosen PP, Snyder RE, Foote FW, Wallace T,. Detection of occult carcinoma in the apparently benign breast biopsy through specimen radiography. Cancer. 1970; 26: 944-952.
236. Nime FA, Rosen PP, Thaler HT, Ashikari R, Urban JA,. Prognostic significance of tumor emboli in intramammary lymphatics in patients with mammary carcinoma. Am J Surg Pathol. 1977; 1: 25-30.
237. Johnson JT, Barnes El, Myers EN, Schramm VL Jr, Borochovitz D, Sigler BA,. The extracapsular spread of tumors in cervical node metastasis. Arch Otolaryngol. 1981; 107: 725-729.
238. Leon SP, Folkerth RD, Black PM,. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer. 1996; 77: 362-372.
239. Counter CM, Avilion AA, LeFeuvre CE, et al., Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992; 11: 1921-1929.
240. Symonds H, Krall L, Remington L, et al., p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 1994; 78: 703-711.
241. Hajdu SI, Urban JA,. Cancers metastatic to the breast. Cancer. 1972; 29: 1691-1696.
242. Martini N, Melamed MR,. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975; 70: 606-612.
243. Rosen PP, Menendez-Botet CJ, Nisselbaum JS, et al., Pathological review of breast lesions analyzed for estrogen receptor protein. Cancer Res. 1975; 35: 3187-3194.
244. Hahnel R, Woodings T, Vivian AB,. Prognostic value of estrogen receptors in primary breast cancer. Cancer. 1979; 44: 671-675.
245. Rosai J, Levine G, Weber WR, Higa E,. Carcinoid tumors and oat cell carcinomas of the thymus. Pathol Annu. 1976; 11: 201-226.
246. Hoon DS, Korn EL, Cochran AJ,. Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans. Cancer Res. 1987; 47: 1740-1744.
247. Barsky SH, Cameron R, Osann KE, Tomita D, Holmes EC,. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer. 1994; 73: 1163-1170.
248. Noguchi M, Morikawa A, Kawasaki M, et al., Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995; 75: 2844-2852.
249. Hajdu SI, Koss LG,. Cytologic diagnosis of metastatic myosarcomas. Acta Cytol. 1969; 13: 545-551.
250. Hajdu SI, Hajdu EO,. Cytopathology of Sarcomas and Other Nonepithelial Malignant Tumors. Philadelphia, PA: WB Saunders; 1976.
251. Hajdu SI,. Exfoliative cytology of primary and metastatic Wilms tumors. Acta Cytol. 1971; 15: 339-342.
252. Lundquist A,. Fine-needle aspiration biopsy for cytodiagnosis of malignant tumors of the liver. Acta Med Scand. 1970; 188: 465-470.
253. Hajdu EO, Kumari-Subaiya S, Philips G,. Ultrasonically guided percutaneous aspiration biopsy of the pancreas. Semin Diagn Pathol. 1986; 3: 166-175.
254. Bell DA, Hajdu SI, Urban JA, Gaston JP,. Role of aspiration cytology in the diagnosis and management of mammary lesions in office practice. Cancer. 1983; 51: 1182-1189.
255. Zaman MB, Hajdu SI, Melamed MR, Watson RC,. Transthoracic aspiration cytology of pulmonary lesions. Semin Diagn Pathol. 1986; 3: 176-187.
256. Hajdu SI, Ehya H, Frable WJ, et al., The value and limitations of aspiration cytology in the diagnosis of primary tumors. A symposium. Acta Cytol. 1989; 33: 741-790.
257. Kaminsky DB,. Aspiration Biopsy for the Community Hospital. New York: Masson; 1981; 235-266.
258. Hajdu SI, Bean MA, Hajdu EO, Ricci A,. Papanicolaou smear of cultured human tumor cells. Acta Cytol. 1974; 18: 327-332.
259. Hajdu SI, Fogh JM,. The nude mouse as a diagnostic tool in human tumor research. In:, Fogh J, Giovanella GC, eds. The Nude Mouse in Experimental and Clinical Research. New York: Academic Press; 1978
260. Hajdu SI, Lemos LB, Kozakewich H, Helson L, Beattie EJ Jr,. Growth pattern and morphology of human soft tissue sarcomas in nude mice. Cancer. 1981; 47: 90-98.
261. Mathe G, Rappaport H, O'Conor GT, Torloni H,. Histological and Cytological Typing of Neoplastic Diseases of Haematopoietic and Lymphoid Tissues. Geneva, Switzerland: World Health Organization; 1976.
262. Erlandson RA,. Diagnostic Transmission Electron Microscopy of Human Tumors. New York: Masson; 1981.
263. Enzinger FM, Weiss SW, eds. Soft Tissue Tumors. St. Louis, MO: CV Mosby; 1984.
264. Hajdu SI,. Differential Diagnosis of Soft Tissue and Bone Tumors. Philadelphia, PA: Lea & Febiger; 1986.
265. Mackay B, Lukeman JM, Ordonez NG, eds. Tumors of the Lung. Philadelphia, PA: WB Saunders; 1991.
266. Ackerman LV, Del Regato JA,. Cancer: Diagnosis, Treatment and Prognosis. St. Louis, MO: CV Mosby; 1947.
267. Ackerman LV,. Verrucous carcinoma of the oral cavity. Surgery. 1948; 23: 670-678.
268. Ackerman LV,. Surgical Pathology. St. Louis, MO: Mosby; 1953.
269. Rosai J,. Ackerman's Surgical Pathology. St. Louis, MO: Mosby; 1995.
270. Hajdu SI,. Medieval pathfinders in surgical oncology. Cancer. 2004; 101: 879-882.
271. Heyn RM, Holland R, Newton WA Jr, Tefft M, Breslow N, Hartmann JR,. The role of combined chemotherapy in the treatment of rhabdomyosarcoma in children. Cancer. 1974; 34: 2128-2142.
272. Rosen G, Wollner N, Tan C, et al., Disease-free survival in children with Ewing's sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy. Cancer. 1974; 33: 384-393.
273. Rosen G,., Murphy ML, Huvos AG, Gutierrez M, Marcove RC,. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer. 1976; 37: 1-11.
274. Fisher B, Slack NH, Cavanaugh PJ, Gardner B, Ravdin RG,. Postoperative radiotherapy in the treatment of breast cancer: results of the NSABP clinical trial. Ann Surg. 1970; 172: 711-732.
275. Fisher B,. Cooperative clinical trials in primary breast cancer: a critical appraisal. Cancer. 1973; 31: 1271-1286.
276. Fisher B, Montague E, Redmond C, et al., Comparison of radical mastectomy with alternative treatments for primary breast cancer. A first report of results from a prospective randomized clinical trial. Cancer. 1977; 39 (6 suppl): 2827-2839.
277. Veronesi U,. Conservative treatment of breast cancer: a trial at the Cancer Institute of Milan. World J Surg. 1977; 1: 324-326.
278. Fisher B, Bauer M, Margolese R, et al., Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985; 312: 665-673.
279. Harris JR, Hellman S, Kinne DW,. Limited surgery and radiotherapy for early breast cancer. N Engl J Med. 1985; 313: 1365-1368.
280. Kurtz JM, Amalric R, Brandone H, et al., Local recurrence after breast-conserving surgery and radiotherapy. Frequency, time course, and prognosis. Cancer. 1989; 63: 1912-1917.
281. Kurtz JM, Jacquemier J, Amalric R, et al., Risk factors for breast recurrence in premenopausal and postmenopausal patients with duct cancers treated by conservation therapy. Cancer. 1990; 65: 1867-1878.
282. Lagios MD, Margolin FR, Westdahl PR, Rose MR,. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer. 1989; 63: 618-624.
283. Wilson RE, Donegan WL, Mettlin C, Natarajan N, Smart CR, Murphy GP,. The 1982 national survey of carcinoma of the breast in the United States by the American College of Surgeons. Surg Gynecol Obstet. 1984; 159: 309-318.
284. Morton DL, Eilber FR, Townsend CM Jr, Grant TT, Mirra J, Weisenburger TH,. Limb salvage from a multidisciplinary treatment approach for skeletal and soft tissue sarcomas of the extremity. Ann Surg. 1976; 184: 268-278.
285. Rosenberg SA, Kent H, Costa J, et al., Prospective randomized evaluation of the role of limb-sparing surgery, radiation therapy, and adjuvant chemoimmunotherapy in the treatment of adult soft-tissue sarcoma. Surgery. 1978; 84: 62-69.
286. Limb-sparing treatment of adult soft tissue sarcomas and osteosarcomas. National Institutes of Health Consensus Development Conference Statement. Natl Inst Health Consens Dev Conf Consens Statement. 1985; 3: 1-5.
287. Williard WC, Hajdu SI, Casper ES, Brennan MF,. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg. 1992; 215: 269-275.
288. Shiu MH, Turnball AD, Nori D, Hajdu SI, Hilaris B,. Control of locally advanced extremity soft tissue sarcomas by function-saving resection and brachytherapy. Cancer. 1984; 53: 1385-1392.
289. Shields TW, Higgins GA Jr,. Minimal pulmonary resection in treatment of carcinoma of the lung. Arch Surg. 1974; 108: 420-422.
290. Eisenberg B, DeCosse JJ, Harford F, Michalek J,. Carcinoma of the colon and rectum: the natural history reviewed in 1704 patients. Cancer. 1982; 49: 1131-1134.
291. Byers RM,. Modified neck dissection. A study of 967 cases from 1970 to 1980. Am J Surg. 1985; 150: 414-421.
292. Hagen JA, Peters JH, DeMeester TR,. Superiority of extended en-bloc esophagectomy for carcinoma of the lower esophagus and cardia. J Thorac Cardiovasc Surg. 1993; 106: 850-858; discussion 858-859.
293. Kadin ME, Glatstein E, Dorfman RF,. Clinicopathologic studies of 117 untreated patients subjected to laparotomy for staging of Hodgkin's disease. Cancer. 1971; 27: 1277-1294.
294. Townsend DE, Richart RM, Marks E, Nielsen J,. Invasive carcinoma following outpatient evaluation and therapy for cervical disease. Obstet Gynecol. 1971; 57; 145-149.
295. Le Roux BT,. Management of bronchial carcinoma by segmental resection. Thorax. 1972; 27: 70-74.
296. Harris MN, Gumport SL, Berman IR, Bernard RW,. Ilioinguinal lymph node dissection for melanoma. Surg Gynecol Obstet. 1973; 136: 33-39.
297. Richardson RH, Zavala DC, Mukerjee PK, Bedell GN,. The use of fiberoptic bronchoscopy and brush biopsy in the diagnosis of suspected pulmonary malignancy. Ann Rev Respir Dis. 1974; 109: 63-66.
298. Griffiths CT,. Surgical resection of the tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975; 42: 101-104.
299. Cabanas RM,. An approach for the treatment of penile carcinoma. Cancer. 1977; 39: 456-466.
300. Morton DL, Wen DR, Wong JH, et al., Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992; 127: 392-399.
301. Guiliano AE, Kirgan DM, Guenther JM, Morton DL,. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994; 220: 391-398; discussion 398-401.
302. Steel HH,. Partial or complete resection of the hemipelvis. An alternative to hindquarter amputation for periacetabular chondrosarcoma of the pelvis. J Bone Joint Surg Am. 1978; 60: 719-730.
303. Lightdale CJ, Hajdu SI,. Brush cytology of the liver and peritoneum at laparoscopy. Gastrointest Endosc. 1978; 24: 169-171.
304. Ozols RF, Fisher RI, Anderson T, Makuch R, Young RC,. Peritoneoscopy in the management of ovarian cancer. Am J Gynecol. 1981; 140: 611-619.
305. Enker WE, Laffer UT, Block GE,. Enhanced survival of patients with colon and rectal cancer is based upon wide anatomic resection. Ann Surg. 1979; 190: 350-360.
306. Walsh PC,. Radical prostatectomy with preservation of sexual function. Urologists' Letter Club. March 24, 1983.
307. Wang KP, Haponik EF, Gupta PK, Erozan YS,. Flexible transbronchial needle aspiration. Technical consideration. Ann Otol Rhinol Laryngol. 1984; 93: 233-236.
308. Heilbrun MP,. Computed tomography-guided stereotactic system. Clin Neurosurg. 1984; 31: 564-581.
309. Georgiade GS, Riefkohl R, Cox E, et al., Long-term clinical outcome of immediate reconstruction after mastectomy. Plast Reconstr Surg. 1985; 76: 415-420.
310. Shah JP,. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg. 1990; 160: 405-409.
311. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH,. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg. 1991; 214: 491-499; discussion 499-501.
312. Parker SH,. Percutaneous large core breast biopsy. Cancer. 1994; 74: 256-262.
313. Fletcher GM, Jessee RH,. The place of irradiation in the management of the primary lesion in head and neck cancers. Cancer. 1977; 39 (2 suppl): 862-867.
314. Cox JD, Komaki J, Byhardt RW, Kun LE,. Results of whole-brain irradiation for metastases from small cell carcinoma of the lung. Cancer Treat Rep. 1980; 64: 957-961.
315. Bergelt B, Gelber R,., Kramer S, et al., The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980; 6: 1-9.
316. Fuller BG, Kaplan ID, Adler J, Cox RS, Bagshaw MA,. Stereotaxic radiosurgery for brain metastases: the importance of adjuvant whole brain irradiation. Int J Radiat Oncol Biol Phys. 1992; 23: 413-418.
317. Lax I, Blomgren H, Naslund I, Svanstrom R,. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspect. Acta Oncol. 1994; 33: 677-683.
318. Holm HH, Juul N, Pederson JF, Hansen H, Stroyer I,. Transperitoneal 125-iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol. 1983; 130: 283-286.
319. Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A,. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 1978; 38: 2628-2635.
320. Farrow JH, Frachia AA, Robbins GF, Castro E,. Simple excision or biopsy plus radiation therapy as the primary treatment for potentially curable cancer of the breast. Cancer. 1971; 28: 1195-1201.
321. Kurtz JM, Spitalier JM, Amalric R,. Late breast recurrence after lumpectomy and irradiation. Int J Radiat Oncol Biol Phys. 1983; 9: 1191-1194.
322. Forrest AP, Stewart HJ, Everington D, et al., Randomized controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. Lancet. 1996; 348: 708-713.
323. Lindberg RD, Martin RG, Romsdahl MM, Barkley HT Jr,. Conservative surgery and postoperative radiation in 300 adults with soft tissue sarcomas. Cancer. 1981; 47: 2391-2397.
324. Fisher B, Wolmark N, Rockette H, et al., Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988; 80: 21-29.
325. Minsky BD, Cohen AM, Hajdu SI, Nori D,. Sphincter preservation in rectal sarcoma. Dis Colon Rectum. 1990; 33: 319-322.
326. Syed AM, Puthwala A, Tansey LA, et al., Management of prostate carcinoma. Combination of pelvic lymphadenectomy, temporary Ir-192 implantation, and external irradiation. Radiology. 1983; 149: 829-833.
327. Van der Werf-Messing B, Menon RS, Hop WC,. Cancer of the urinary bladder T2, T3 (NxMo) treated by interstitial radium implant: second report. Int J Radiat Oncol Biol Phys. 1983; 9: 481-485.
328. Prempree T,. Parametrial implant in stage III B cancer of the cervix. III. A five-year study. Cancer. 1983; 52: 746-750.
329. Shiu MH, Collin C, Hilaris BS, et al., Limb preservation and tumor control in the treatment of popliteal and antecubital soft tissue sarcomas. Cancer. 1986; 57: 1632-1639.
330. Green N, Kurohara SS, George FW, 3rd, Crews QE Jr,. Postresection irradiation for primary lung cancer. Radiology. 1975; 116: 405-407.
331. Wallgren A, Arner O, Bergstrom J, et al., Preoperative radiotherapy in operable breast cancer: results in the Stockholm Breast Cancer Trial. Cancer. 1978; 42: 1120-1125.
332. Whitmore WF Jr, Batata MA, Ghoneim MA, Grabstald H, Unal A,. Radical cystectomy with or without prior irradiation in the treatment of bladder cancer. J Urol. 1977; 118: 184-187.
333. Suit HD, Proppe KH, Mankin HJ, Wood WC,. Preoperative radiation therapy for sarcoma of soft tissue. Cancer. 1981; 47: 2269-2274.
334. Cedermark B, Johansson H, Rutqvist LE, Wilking N,. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer. 1995; 75: 2269-2275.
335. Warram J,. Preoperative irradiation of cancer of the lung: final report of a therapeutic trial. A collaborative study. Cancer. 1975; 36: 914-925.
336. Rosenberg SA, Tepper J, Glatstein E, et al., The treatment of soft tissue sarcomas of the extremities: prospective randomized evaluation of 1) limb-sparing surgery plus radiation therapy compared with amputation and 2) the role of adjuvant chemotherapy. Ann Surg. 1982; 196: 305-315.
337. Grohn P, Heinonen E, Klefstrom P, Tarkkanen J,. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. Cancer. 1984; 54: 670-674.
338. Buzdar AU, McNeese MD, Hortobagyi GN, et al., Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer? Cancer. 1990; 65: 394-399.
339. Wertheim MS, Hakes TB, Daghestani AN, Nori D, Smith DH, Lewis JL Jr,. A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol. 1985; 3: 912-916.
340. Kushner BH, Hajdu SI, Gulati SC, Erlandson RA, Exelby PR, Lieberman PH,. Extracranial primitive neuroectodermal tumors. The Memorial Sloan-Kettering Cancer Center experience. Cancer. 1991; 67: 1825-1829.
341. Vokes EE, Weichselbaum RR,. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol.1 1990; 8: 911-934.
342. Jeremic B, Shibamoto Y, Acimovic L, Djuric L,. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 1995; 13: 452-458.
343. Jaffe N, Frei E, 3rd, Traggis D, Bishop Y,. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med. 1974; 291: 994-997.
344. Miser JS, Kinsella TJ, Triche TJ, et al., Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987; 5: 1191-1198.
345. Eilber F, Giuliano A, Eckaradt J, Patterson K, Moseley S, Goodnight J,. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987; 5: 21-26.
346. Sordillo PP, Magill GB, Shiu MH, Lesser M, Hajdu SI, Golbey RB,. Adjuvant chemotherapy of soft part sarcomas with ALOMAD. J Surg Oncol. 1981; 18: 345-353.
347. Rosenberg SA, Tepper J, Glatstein E, et al., Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer. 1983; 52: 424-434.
348. Fisher B, Carbone P, Economu SG, et al., 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med. 1975; 292: 117-122.
349. Bonadonna G, Brusamolino E, Valagussa P, et al., Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976; 294: 405-410.
350. Fisher B, Slack N, Katrrych D, Wolmark N,. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet. 1975; 140: 528-534.
351. Cannelos GP, DeVita VT Jr, Gold GL, Chabner BA, Schein PS, Young RD,. Cyclical combination chemotherapy for advanced breast carcinoma. Br Med J. 1974; 1: 218-220.
352. Bonadonna G, Valagus P, Rossi A, et al., Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat. 1985; 5: 95-115.
353. Fisher B, Fisher ER, Redmond C,. Ten year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol. 1986; 4: 929-941.
354. Arcamone F, Cassinelli G, Fantini G, et al., Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng. 1969; 11: 1101-1110.
355. Bonadonna G, Monfardini S, de Lena M, Fossati-Bellani F, Beretta G,. Phase I and preliminary phase II evaluation of Adriamycin (NSC 123127). Cancer Res. 1970; 30: 2572-2582.
356. Harper MJK, Walpole AL,. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil. 1967; 13: 101-119.
357. Jordan VC, Koerner S,. Tamoxifen (ICI 46,474), and the human carcinoma 8S oestrogen receptor. Eur J Cancer. 1975; 11: 205-206.
358. Jordan VC,. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinoma. Eur J Cancer. 1976; 12: 419-424.
359. Cole MP, Jones CT, Todd ID,. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46, 474. Br J Cancer. 1971; 25: 270-275.
360. Cole MP, Jones CT, Todd ID,. The treatment of advanced carcinoma of the breast with the antiestrogenic agent tamoxifen (ICI 46,474)-a series of 96 patients. In:, Hejzlar M, Semonsky M, Masak S, eds. Advances in Antimicrobial and Antineoplastic Chemotherapy. Proceedings of the Seventh International Congress of Chemotherapy, Prague. Baltimore, MD: University Park Press; 1972; 529-531.
361. Ward HW,. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J. 1973; 1: 13-14.
362. Clark GM, McGuire WL, Hubay CA, Pearson OH, Carter AC,. The importance of estrogen and progesterone receptor in primary breast cancer. Prog Clin Biol Res. 1983; 132E: 183-190.
363. Fisher B, Redmond C, Brown A, et al., Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981; 305: 1-6.
364. Cuzick J, Baum M,. Tamoxifen and contralateral breast cancer [letter]. Lancet. 1985; 2: 282.
365. Fisher B, Dignam J, Bryant J, et al., Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996; 88: 1529-1542.
366. Terenius L,. Structure-activity relationships of anti-oestrogens with regard to interaction with 17-beta-oestradiol in the mouse uterus and vagina. Acta Endocrinol. 1971; 66: 431-437.
367. Boccardo F, Bruzzi P, Rubagotti A, Nicolo GU, Rosso R,. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology. 1981; 38: 281-285.
368. Killackey MA, Hakes TB, Pierce VK,. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep. 1985; 69: 237-238.
369. Fornander T, Rutquist LE, Cedarmark B, et al., Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989; 1: 117-120.
370. Samuels ML, Johnson DE, Holoye PY,. Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine in stage III testicular neoplasms. Cancer Chemother Rep. 1975; 59: 563-570.
371. Einhorn LH, Donohue JP,. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977; 87: 293-298.
372. Adjuvant therapy of colon cancer-results of a prospectively randomized trial. Gastrointestinal Tumor Study Group. N Engl J Med. 1984; 310: 737-743.
373. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264: 1444-1450.
374. Yagoda A,. Future implications of phase II chemotherapy trials in 95 patients with measurable advanced bladder cancer. Cancer Res. 1977; 37: 2775-2780.
375. Reiner WG, Scott WW, Eggleston JC, Walsh PC,. Long-term survival after hormonal therapy for stage D prostate cancer. J Urol. 1979; 122: 183-184.
376. Huang AT, Cole TB, Fishburn R, Jelovsek SB,. Adjuvant chemotherapy after surgery and radiation for stage III and IV head and neck cancer. Ann Surg. 1984; 200: 195-199.
377. Burke PJ, McCarthy WH, Milton GW,. Imidazole carboxamide therapy in advanced malignant melanoma. Cancer. 1971; 27: 744-750.
378. Wittes RE, Wittes JT, Golbey RB,. Combination chemotherapy in metastatic malignant melanoma. A randomized study of three DTIC-containing combinations. Cancer. 1978; 41: 415-421.
379. Gollin FF, Johnson RO,. Preirradiation 5-fluorouracil infusion in advanced head and neck carcinomas. Cancer. 1971; 27: 768-770.
380. Schuller DE, Wilson HE, Smith RE, Batley F, James AD,. Preoperative reductive chemotherapy for locally advanced carcinoma of the oral cavity, oropharynx, and hypopharynx. Cancer. 1983; 51: 15-19.
381. Rosell R, Gomez-Codina J, Camps C, et al., A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994; 330: 153-158.
382. Goldie JH,. Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol. 1987; 14: 1-7.
383. Benedetti Panici P, Scambia G, Greggi S, Di Roberto P, Baiocchi G, Mancuso S,. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical carcinoma: a pilot study. Obstet Gynecol. 1988; 71: 344-348.
384. Ragaz J, Baird R, Rebbeck P, Goldie J, Coldman A, Spinelli J,. Neoadjuvant (preoperative) chemotherapy for breast cancer. Cancer. 1985; 56: 719-724.
385. Whelan T, Clark R, Roberts R, Levine M, Foster G,. Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from randomized trial. Investigators of the Ontario Clinical Oncology Group. Int J Radiat Oncol Biol Phys. 1994; 30: 11-16.
386. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG,. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986; 315: 663-666.
387. Kalwinsky D, Mirro J Jr, Schell M, Behm F, Mason C, Dahl GV,. Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a 5-drug regimen including etoposide. J Clin Oncol. 1988; 6: 1134-1143.
388. Fefer A, Cheever MA, Greenberg PD, et al., Treatment of chronic granulocytic leukemia with chemotherapy and transplantation of marrow from identical twin. N Engl J Med. 1982; 306: 63-68.
389. Dahl GV, Kalwinsky DK, Mirro J Jr, et al., Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission. J Clin Oncol. 1990; 8: 295-303.
390. Selby P, Zulian G, Forgeson G, et al., The development of high dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St Bartholomew's Hospital studies. Hematol Oncol. 1988; 6: 173-179.
391. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C,. Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975; 36: 252-259.
392. DeVita VT Jr, Simon RM, Hubbard SM, et al., Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP treated patients at the National Cancer Institute. Ann Intern Med. 1980; 92: 587-595.
393. Berd D, Cornog J, DeConti RC, Levitt M, Bertino JR,. Long-term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy. Cancer. 1975; 35: 1050-1054.
394. DeVita VT Jr, Cannellos GP, Chabner B, Schein P, Hubbard SP, Young RC,. Advanced diffuse histiocytic lymphoma a potentially curable disease: results with combination chemotherapy. Lancet. 1975; 1: 248-250.
395. Velasquez WS, McLaughlin P, Tucker S, et al., ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994; 12: 1169-1176.
396. Philip T, Guglielmi C, Hagenbeek A, et al., Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333: 1540-1545.
397. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr,. Pharmacokinetic rationale for peritoneal drug administration in treatment of ovarian cancer. Cancer Treat Rep. 1978; 62: 1-11.
398. Spratt JS, Adcock RA, Muskovin M, et al., Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980; 40: 256-260.
399. Kato T, Nemoto R, Mori H, Takahashi M, Tamakawa Y, Harada M,. Arterial embolization with microencapsulated anticancer drug. An approach to selective cancer chemotherapy with sustained effects. JAMA. 1981; 245; 1123-1127.
400. DeLena M, Guzzon A, Monfardini S, Bonadonna G,. Clinical, radiologic, and histopathologic studies on pulmonary toxicity induced by treatment with bleomycin (NSC-125066). Cancer Chemother Rep. 1972; 56: 343-356.
401. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA,. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer. 1973; 32: 302-314.
402. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS,. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer. 1977; 39: 1362-1371.
403. Hande KR, Garrow GC,. Acute tumor lysis syndrome in patients with high grade non-Hodgkin's lymphoma. Am J Med. 1993; 94: 133-139.
404. Reimer RR, Hoover R, Fraumeni JF Jr, Young RC,. Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med. 1977; 297: 177-181.
405. Morales A, Eidinger D, Bruce AW,. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976; 116: 180-183.
406. Utz DC, Farrow GM, Rife CC, Segura JW, Zincke H,. Carcinoma in situ of the bladder. Cancer. 1980; 45 (7 suppl): 1842-1848.
407. Lamm DL, Thor DE, Winters WD, Stogdill VD, Radwin HM,. BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses. Cancer. 1981; 48: 82-88.
408. Laucius JF, Bodurtha AJ, Mastrangelo MJ, Bellet RE,. A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma. Cancer. 1977; 40: 2091-2093.
409. Wallack MK,. Specific tumor immunity produced by the injection of vaccinia viral oncolysates. J Surg Res. 1982; 33: 11-16.
410. Hellstrom I, Hellstrom KE, Sjogren HO, Warner GA,. Demonstration of cell-mediated immunity to human neoplasia of various histological types. Int J Cancer. 1971; 7: 1-16.
411. Kohler G, Milstein C,. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256: 495-499.
412. Nadler LM, Stashenko P, Hardy R, et al., Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980; 40: 3147-3154.
413. Ritz J, Pesando JM, Sallan SE, et al., Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood. 1981; 58: 141-152.
414. Schultz RM, Papamatheakis JD, Chirigos MA,. Interferon: an inducer of macrophage activation by polyanions. Science. 1977; 197: 674-676.
415. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA,. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med. 1982; 155: 1823-1841.
416. Kirkwood JM, Ernstoff MS,. Interferons in the treatment of human cancer. J Clin Oncol. 1984; 2: 336-352.
417. Crown SE, Mintzer D, Cunningham-Rundles S, et al., High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biologic responses. Cancer Treat Rep. 1987; 71: 39-45.
418. Faltynek CR, Princler GL, Rossio JL, et al., Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative disease. Blood. 1986; 67: 1077-1082.
419. Rosenberg SA, Lotze MT, Muul LM, et al., A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 alone. N Engl J Med. 1987; 316: 889-897.
420. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A,. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994; 12: 337-365.
421. Rosenberg SA, Yang JC, Topalian SL, et al., Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA. 1994; 271: 907-913.
422. Dennert G, Lotan R,. Effect of retinoic acid on the immune system: stimulation of T killer cell induction. Eur J Immunol. 1978; 8: 23-29.
423. North RJ,. Radiation-induced immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells. J Exp Med. 1986; 164: 1652-1666.
424. Mendelsohn J,. Growth factor receptors as targets for antitumor therapy with monoclonal antibodies. Prog Allergy. 1988; 45: 147-160.
425. Chang K, Pastan I,. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 1996; 93: 136-140.
426. Time Inc. Hope in the war against cancer. Time. April 24, 1994.
427. Kurihara M, Aoki K, Tominaga S, eds. Cancer Mortality Statistics in the World. Nagoya, Japan: University of Nagoya Press; 1984.
428. Waterhouse J, Muir C, Shanmugaratnam K, Powell J, eds. Cancer in Five Continents. Lyon, France: IARC Press; 1989.
429. Davis DL, Hoel D, Fox J, Lopez A,. International trends in cancer mortality in France, West Germany, Italy, Japan, England and Wales, and the USA. Lancet. 1990; 336: 474-481.
430. US National Cancer Institute. Cancer Statistics Review 1973-1987. Bethesda, MD: National Institutes of Health; 1990.
431. Office of Population Censuses and Surveys. Cancer Statistics Registrations, 1985 (Series MBI, No. 18). London, UK: HM Stationery Office; 1990.
432. Ries LG, Pollack ES, Young JL,. Cancer patient survival: Surveillance, Epidemiology, and End Results Program, 1973-79. J Natl Cancer Inst. 1983; 70: 693-707.
433. Wingo PA, Tong T, Bolden S,. Cancer statistics, 1995. CA Cancer J Clin. 1995; 45: 8-30.
434. Miller RW, Young JL, Novakovic B,. Childhood cancer. Cancer. 1995; 75: 395-405.
435. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
436. Centers for Disease Control and Prevention. Ten great public health achievements-United States, 1990-1999. Morb Mortal Wkly Rep. 1999; 48: 241-243.
437. Wolff J,. Die Lehre von der Krebskrankheit von den altesten Zeiten bis zur Gegenwart. 4 vols. Jena, Germany: Fischer; 1907-1928.
438. Shimkin MB,. Contrary to Nature. Washington, DC: US Department of Health, Education, and Welfare; 1977.